Leor Porat - Allovir Executive Vice President General Counsel

ALVR
 Stock
  

USD 7.62  0.23  3.11%   

  President
Mr. Leor Porat is Executive Vice President General Counsel of Alvarion Ltd. He joined Alvarion in June 2012 as Vice President General Counsel. Prior to joining Alvarion Mr. Porat served as General Counsel and head of the legal department at Syneron Medical Ltd. . Between 2004 to 2006 Mr. Porat was an associate at Meitar Liquornik Geva Leshem Brandwein law firm where his practice focused on corporate law and MA transactions
Age: 38  President Since 2012      
617 433 2605  https://www.allovir.com
Porat holds a dual, a B.A. in Economics and L.L.B from the Hebrew University in Jerusalem.

Allovir Management Efficiency

Allovir has return on total asset (ROA) of (39.1) % which means that it has lost $39.1 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (70.84) %, meaning that it created substantial loss on money invested by shareholders. Allovir management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 23.13 M in liabilities with Debt to Equity (D/E) ratio of 0.12, which may suggest the company is not taking enough advantage from borrowing. Allovir has a current ratio of 10.86, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Allovir until it has trouble settling it off, either with new capital or with free cash flow. So, Allovir's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Allovir sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Allovir to invest in growth at high rates of return. When we think about Allovir's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 6 records

PRESIDENT Since

Kari MoyesClearwater Paper Corp
2015
Robert HrivnakClearwater Paper Corp
2020
Arsen KitchClearwater Paper Corp
2020
Michael GaddClearwater Paper Corp
2011
Michael MurphyClearwater Paper Corp
2020
Patrick BurkeClearwater Paper Corp
2017
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell therapies to prevent and treat devastating viral-associated diseases. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts. Allovir operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 110 people. Allovir (ALVR) is traded on NASDAQ Exchange in USA and employs 110 people.

Allovir Leadership Team

Elected by the shareholders, the Allovir's board of directors comprises two types of representatives: Allovir inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Allovir. The board's role is to monitor Allovir's management team and ensure that shareholders' interests are well served. Allovir's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Allovir's outside directors are responsible for providing unbiased perspectives on the board's policies.
Doron Inbar, Non-Executive Independent Director
Raphael Amit, External Director
Zeev Farkash, Executive Vice President - Sales
Assaf Katan, Acting President and CEO
Moshe Fourier, Executive Vice President-R&D
Tali Aben, Non-Executive Independent Director
Mati Wax, CTO
Avi Stern, CFO
Amnon Yacoby, Independent Chairman of the Board
Nir Golan, Executive Vice President
Ziv Eizenberg, Executive Vice President-Human Resources
Leor Porat, Executive Vice President General Counsel

Allovir Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Allovir a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Allovir in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Allovir's short interest history, or implied volatility extrapolated from Allovir options trading.

Pair Trading with Allovir

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Allovir position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Allovir will appreciate offsetting losses from the drop in the long position's value.

Moving together with Allovir

+0.81DISWalt Disney Fiscal Year End 9th of November 2022 PairCorr
The ability to find closely correlated positions to Allovir could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Allovir when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Allovir - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Allovir to buy it.
The correlation of Allovir is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Allovir moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Allovir moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Allovir can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Please continue to Trending Equities. You can also try Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.

Complementary Tools for analysis

When running Allovir price analysis, check to measure Allovir's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allovir is operating at the current time. Most of Allovir's value examination focuses on studying past and present price action to predict the probability of Allovir's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Allovir's price. Additionally, you may evaluate how the addition of Allovir to your portfolios can decrease your overall portfolio volatility.
CEO Directory
Screen CEOs from public companies around the world
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Is Allovir's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allovir. If investors know Allovir will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allovir listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Allovir is measured differently than its book value, which is the value of Allovir that is recorded on the company's balance sheet. Investors also form their own opinion of Allovir's value that differs from its market value or its book value, called intrinsic value, which is Allovir's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allovir's market value can be influenced by many factors that don't directly affect Allovir's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Allovir's value and its price as these two are different measures arrived at by different means. Investors typically determine Allovir value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allovir's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.